文章：

中心型非小细胞肺癌碳离子消融放疗的长期疗效：一项单中心回顾性研究

Long-Term Outcomes of Ablative Carbon-Ion Radiotherapy for Central Non-Small Cell Lung Cancer: A Single-Center, Retrospective Study

原文发布日期：25 February 2024

DOI: 10.3390/cancers16050933

类型: Article

开放获取: 是

英文摘要：

The aim of this study is to assess the efficacy and safety of ablative carbon ion radiotherapy (CIRT) for early stage central non-small cell lung cancer (NSCLC). We retrospectively reviewed 30 patients who had received CIRT at 68.4 Gy in 12 fractions for central NSCLC in 2006–2019. The median age was 75 years, and the median Karnofsky Performance Scale score was 90%. All patients had concomitant chronic obstructive pulmonary disease, and 20 patients (67%) were considered inoperable. In DVH analysis, the median lung V5 and V20 were 15.5% and 10.4%, and the median Dmax, D0.5cc, D2cc of proximal bronchial tree was 65.6 Gy, 52.8 Gy, and 10.0 Gy, respectively. At a median follow-up of 43 months, the 3-year overall survival, disease-specific survival, and local control rates were 72.4, 75.8, and 88.7%, respectively. Two patients experienced grade 3 pneumonitis, but no grade ≥3 adverse events involving the mediastinal organs occurred. Ablative CIRT is feasible and effective for central NSCLC and could be considered as a treatment option, especially for patients who are intolerant of other curative treatments.

摘要翻译： 

本研究旨在评估消融性碳离子放疗（CIRT）治疗早期中央型非小细胞肺癌（NSCLC）的有效性和安全性。我们回顾性分析了2006年至2019年间接受68.4 Gy/12次分割CIRT治疗的30例中央型NSCLC患者。患者中位年龄75岁，中位卡氏功能状态评分90%。所有患者均合并慢性阻塞性肺疾病，其中20例（67%）被认为无法手术。剂量体积直方图分析显示：中位肺V5和V20分别为15.5%和10.4%；近端支气管树的中位Dmax、D0.5cc和D2cc分别为65.6 Gy、52.8 Gy和10.0 Gy。中位随访43个月后，3年总生存率、疾病特异性生存率和局部控制率分别为72.4%、75.8%和88.7%。2例患者出现3级放射性肺炎，但未发生≥3级的纵隔器官相关不良事件。消融性CIRT治疗中央型NSCLC具有可行性和有效性，可作为治疗选择，尤其适用于无法耐受其他根治性治疗的患者。

原文链接：

Long-Term Outcomes of Ablative Carbon-Ion Radiotherapy for Central Non-Small Cell Lung Cancer: A Single-Center, Retrospective Study